New Publication in Vaccine Highlights Preclinical Results of Vaxart’s Mucosal Chikungunya Vaccine
The article, titled “An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling,” details the results from a study using Vaxart’s chikungunya vaccine candidate in a preclinical efficacy model.
“These preclinical results demonstrate that our vaccine candidate
induced significant neutralizing antibodies against chikungunya virus as
well as protective efficacy against virus-induced pathologic changes,”
said
About Chikungunya
Chikungunya is an illness caused by a virus that spreads through
mosquito bites. The most common symptoms of chikungunya are fever and
joint pain. Other symptoms may include headache, muscle pain, joint
swelling, or rash. The mosquito that carries chikungunya virus bites
primarily during the daytime, both indoors and outdoors, and often lives
around buildings in urban areas. Patients symptoms usually begin 3—7
days after being bitten by an infected mosquito. Most patients will feel
better within a week. In some people, the joint pain may persist for
months. Death is rare. People at risk for more severe disease include
newborns infected around the time of birth, older adults (≥65 years),
and people with medical conditions such as high blood pressure,
diabetes, or heart disease. Travelers who go to
About
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, results from preclinical
and clinical trials, commercialization agreements and licenses, beliefs
and expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
“believe,” “could,” “potential,” “will” and other words and terms of
similar meaning. Examples of such statements include, but are not
limited to, statements relating to the Vaxart’s ability to develop and
commercialize its product candidates and clinical results and trial
data; the expected timing of the initiation of the Phase 1 bivalent
study and Phase 2 monovalent challenge study; and Vaxart’s expectations
with respect to the important advantages it believes its oral vaccine
platform can offer over injectable alternatives, particularly for
mucosal pathogens such as norovirus, flu and RSV.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005267/en/
Source:
Daniella Funaro
Stern Investor Relations
212-362-1200
vaxart@sternir.com